Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on: December 26,2023

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on:December 26,2023

American cancer survivors face substantial financial hardship and financial sacrifices

byAmerican Association for Cancer ResearchAmerican cancer survivors, particularly those 64 years or younger, faced substantial medical financial hardship and sacrifices in spending, savings, or

Updated on: December 20,2023

American cancer survivors face substantial financial hardship and financial sacrifices

byAmerican Association for Cancer ResearchAmerican cancer survivors, particularly those 64 years or younger, faced substantial medical financial hardship and sacrifices in spending, savings, or

Updated on:December 20,2023

Fourth SARS-CoV-2 vaccination also protects cancer patients

by Johannes Angerer,Medical University of ViennaReceptor-Binding Domain and Angiotensin-Converting Enzyme 2 Interaction Inhibition in Patients With Hematologic Malignant Neoplasm With or Without

Updated on: December 20,2023

Fourth SARS-CoV-2 vaccination also protects cancer patients

by Johannes Angerer,Medical University of ViennaReceptor-Binding Domain and Angiotensin-Converting Enzyme 2 Interaction Inhibition in Patients With Hematologic Malignant Neoplasm With or Without

Updated on:December 20,2023

Gene loss enhances metastasis and cancer progression

by Melissa Rohman,Northwestern UniversityAn in vivo genome-wide CRISPR-Cas9 KO screen identifying CTC-promoting genetic factors. (A) Experimental design of the genome-wide CRISPR-Cas9 KO screen

Updated on: December 25,2023

Gene loss enhances metastasis and cancer progression

by Melissa Rohman,Northwestern UniversityAn in vivo genome-wide CRISPR-Cas9 KO screen identifying CTC-promoting genetic factors. (A) Experimental design of the genome-wide CRISPR-Cas9 KO screen

Updated on:December 25,2023

Study shows clinical benefit of a new way of treating advanced ER+ breast cancer

by University of LiverpoolCredit: Unsplash/CC0 Public DomainA research paper published today inThe Lancet Oncologydemonstrates that the drug enobosarm, a selective androgen receptor m

Updated on: May 26,2024

Study shows clinical benefit of a new way of treating advanced ER+ breast cancer

by University of LiverpoolCredit: Unsplash/CC0 Public DomainA research paper published today inThe Lancet Oncologydemonstrates that the drug enobosarm, a selective androgen receptor m

Updated on:May 26,2024

Defensive beliefs likely keep people from taking at-home stool tests that screen for colorectal cancer

byWileyCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Colorectal cancer is one of the most treatable cancers, especially if it is detected early; however, many

Updated on: December 22,2023

Defensive beliefs likely keep people from taking at-home stool tests that screen for colorectal cancer

byWileyCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Colorectal cancer is one of the most treatable cancers, especially if it is detected early; however, many

Updated on:December 22,2023

Scientists discover metabolic feature that allows melanoma cells to spread

by Katie Regan,UT Southwestern Medical CenterResearchers involved in the study include (from left) Drs. Brandon Faubert, Alpaslan Tasdogan, Sean Morrison, and Ralph DeBerardinis. Credit: UTSWRes

Updated on: December 23,2023

Scientists discover metabolic feature that allows melanoma cells to spread

by Katie Regan,UT Southwestern Medical CenterResearchers involved in the study include (from left) Drs. Brandon Faubert, Alpaslan Tasdogan, Sean Morrison, and Ralph DeBerardinis. Credit: UTSWRes

Updated on:December 23,2023

Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro

Updated on: March 22,2024

Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro

Updated on:March 22,2024

Study shows which patients with advanced prostate cancer will benefit from chemotherapy

by University College LondonProstate cancer cells. Credit: NIH Image GalleryResearchers have recommended changes to how cancer patients are treated, after a new UCL-led study discovered that chem

Updated on: April 03,2024

Study shows which patients with advanced prostate cancer will benefit from chemotherapy

by University College LondonProstate cancer cells. Credit: NIH Image GalleryResearchers have recommended changes to how cancer patients are treated, after a new UCL-led study discovered that chem

Updated on:April 03,2024

A blood sample 24 hours after the start of chemotherapy can predict survival

byUniversity of BergenMass cytometry analysis of early response evaluation by single-cell signaling to profile.aPeripheral blood samples were collected from 32 AML patients treated w

Updated on: December 25,2023

A blood sample 24 hours after the start of chemotherapy can predict survival

byUniversity of BergenMass cytometry analysis of early response evaluation by single-cell signaling to profile.aPeripheral blood samples were collected from 32 AML patients treated w

Updated on:December 25,2023

FDA approves Vyloy for advanced gastric or gastroesophageal junction cancer

by Lori SolomonThe U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of a

Updated on: November 07,2024

FDA approves Vyloy for advanced gastric or gastroesophageal junction cancer

by Lori SolomonThe U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of a

Updated on:November 07,2024

New patient guidelines for marginal zone lymphoma help caregivers better understand a rare form of blood cancer

by National Comprehensive Cancer NetworkNCCN Guidelines for Patients: Marginal Zone Lymphoma now available for free at NCCN.org/patientinformation. Credit: NCCNThe National Comprehensive Cancer Networ

Updated on: January 11,2024

New patient guidelines for marginal zone lymphoma help caregivers better understand a rare form of blood cancer

by National Comprehensive Cancer NetworkNCCN Guidelines for Patients: Marginal Zone Lymphoma now available for free at NCCN.org/patientinformation. Credit: NCCNThe National Comprehensive Cancer Networ

Updated on:January 11,2024